osteosarcoma
osteosarcoma
Explore linked clinical trials. Standard reference: MONDO:0009807183 results · Page 1 of 8
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-10-09 | NCT04320888 | |
| A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, bone disorder, connective tissue neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, sarcoma | Active, not recruiting | Phase 1 | 2026-10-08 | NCT05312411 | |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Eye Diseases, Hereditary, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, eye disorder, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-10-08 | NCT03618381 | |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | Disease Attributes, Ewing sarcoma, Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, connective tissue neoplasm, epithelial neoplasm, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, rhabdomyosarcoma, sarcoma | Recruiting | Phase 1 | 2026-10-08 | NCT02013336 | |
| Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-10-07 | NCT07787429 | |
| To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-10-07 | NCT05968768 | |
| Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-10-07 | NCT05588648 | |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-10-06 | NCT07321912 | |
| Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, round cell sarcoma with EWSR1-non-ETS fusion, sarcoma | Recruiting | Not applicable | 2026-10-06 | NCT07188532 | |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Ewing sarcoma, Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, connective tissue neoplasm, epithelial neoplasm, liposarcoma, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, rhabdomyosarcoma, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT06541262 | |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Ewing sarcoma, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Tumor Virus Infections, connective tissue neoplasm, diffuse large B-cell lymphoma, epithelial neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, sarcoma, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT06395103 | |
| Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-10-06 | NCT05019703 | |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, central nervous system cancer, connective tissue neoplasm, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT03213652 | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, peripheral primitive neuroectodermal tumor of soft tissues, sarcoma | Active, not recruiting | Phase 3 | 2026-10-06 | NCT02306161 | |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, bone cancer, bone disorder, connective tissue neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, sarcoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT07853105 | |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, astrocytoma (excluding glioblastoma), benign urinary system neoplasm, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, ependymoma, epithelial neoplasm, glioblastoma, glioma, gliosarcoma, hereditary disease, hereditary neoplastic syndrome, immune system disorder, immunoproliferative disorder, kidney cancer, kidney disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, pediatric lymphoma, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-10-01 | NCT03478462 | |
| Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 1 | 2026-09-30 | NCT06492954 | |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, connective tissue neoplasm, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, sarcoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-30 | NCT03373097 | |
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, connective tissue neoplasm, desmoplastic small round cell tumor, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, neoplasm, osteosarcoma, sarcoma, urinary system disorder | Recruiting | Phase 2 | 2026-09-29 | NCT04616560 | |
| The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-09-25 | NCT07560826 | |
| Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) | Disease Attributes, Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 1 | 2026-09-25 | NCT07297979 | |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 1 | 2026-09-25 | NCT07194044 | |
| Olaparib With Ceralasertib in Recurrent Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Active, not recruiting | Phase 2 | 2026-09-24 | NCT04417062 | |
| A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors | Ewing sarcoma, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, osteosarcoma, prostate cancer, prostate disorder, sarcoma | Recruiting | Phase 1 | 2026-09-23 | NCT06926283 | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Stomatognathic Diseases, Thyroid Cancer, Papillary, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, benign urinary system neoplasm, brain disorder, carcinoma, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, glioma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, malignant endocrine neoplasm, medulloblastoma, mesoblastic nephroma, mixed neoplasm, mouth disorder, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, papillary adenocarcinoma, primitive neuroectodermal tumor, salivary gland cancer, salivary gland disorder, sarcoma, thyroid gland disorder, thyroid tumor, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT02650401 |